Founder of Blueprint. Built a business by scraping 25M+ job posts to find company pain points. Believes the Predictable Revenue model is dead. Thinks mounting an AI SDR on outdated methodology is like putting a legless robot on a horse - no one gets anywhere, and it still shits along the way.
The core philosophy is simple: The message isn't the problem. The LIST is the message. When you know exactly who to target and why they need you right now, the message writes itself.
What they do: Inpharmativ provides precision data intelligence for pharmaceutical companies launching products in specialized therapeutic areas in Canada. They specialize in KOL (Key Opinion Leader) mapping, treatment pattern analysis, and market entry strategy for companies entering new therapeutic areas without established presence.
Founder: Steve Walters - former pharmaceutical sales rep with 12 years of industry experience who identified gaps in KOL targeting accessibility for companies launching in niche markets.
Target customers: Pharmaceutical and biotech companies launching innovative therapies in Canada, particularly in oncology, rare disease, and neurosurgery - areas where they lack existing KOL relationships.
Value proposition: "Precision Data Intelligence" - a proprietary blend of algorithmic data collection with manual verification, enabling teams to build stakeholder relationships quickly without expanding headcount.
Let's be brutally honest about what typical pharmaceutical data services do. They buy generic physician lists, send templated outreach about "helping with your commercial launch," and hope someone bites. Here's what it actually looks like:
The Typical Generic Outreach:
Why this fails: The prospect - a VP of Commercial or Medical Affairs - has seen this exact template from every data vendor in their inbox. There's zero indication you know WHICH product they're launching, WHEN they received approval, or WHAT therapeutic area they're entering. It's interruption disguised as helpfulness. Delete.
Firmographics: Pharma/biotech companies with new Health Canada drug approvals, active clinical trials, or recent CADTH positive recommendations - especially in oncology, rare disease, and specialized therapeutic areas.
Behavioral signals: First product launch in Canada, no existing commercial infrastructure, limited existing KOL relationships in therapeutic area.
Pain indicators: Building from scratch while competitors have established networks; navigating provincial formulary processes without clinical champions; managing pre-launch KOL engagement across 10 provinces.
Titles: VP Commercial, Head of Canadian Operations, Medical Affairs Director, VP Market Access, Commercial Lead
Responsibilities: Launch strategy, KOL engagement, formulary submissions, provincial payer relationships, building prescriber awareness
KPIs: Time to first prescription, formulary listing timeline, KOL engagement rate, prescriber awareness metrics
Daily challenges: Building relationships from scratch in unfamiliar therapeutic areas, navigating Canada's provincial payer landscape, identifying the right physicians to engage pre-launch
Blueprint flips the entire approach. Instead of interrupting prospects with pitches, you deliver insights so valuable they'd pay consulting fees to receive them. You become the person who helps them see around corners, not another vendor in their inbox.
This requires two fundamental shifts:
Stop: "I see you're launching a new product in Canada" (everyone knows this)
Start: "Your December 2025 NOC for [Drug] (DIN: 02XXXXXX) under ATC L01 marks your first Canadian oncology product" (Health Canada DPD with specific identifiers)
PQS (Pain-Qualified Segment): Reflect their exact situation with such specificity they think "how did you know?" Use Health Canada databases, CADTH recommendations, and provincial formularies with dates and record numbers.
PVP (Permissionless Value Proposition): Deliver immediate value they can use today - analysis already done, gaps already identified, timelines already calculated - whether they buy or not.
These messages demonstrate such precise understanding of the prospect's current situation that they feel genuinely seen. Every claim traces to a specific Canadian government database with verifiable record numbers. All 6 plays below are PQS messages - strong pain identification using exclusively Canadian data sources.
Target pharmaceutical companies that just received Health Canada approval (Notice of Compliance) for drugs in specialized therapeutic areas like oncology. These companies have an immediate, urgent need to identify and engage KOLs before launch - but if it's their first Canadian product, they have no existing relationships to leverage.
The message proves you've done real research by citing the specific DIN, authorization date, and ATC therapeutic classification. It then surfaces the competitive disadvantage they're experiencing - building from scratch while competitors have established networks. The routing question is low-effort and non-threatening.
Primary: Health Canada Drug Product Database (DPD) - Search by ATC code (L01 for antineoplastic), filter by "Approved" or "Marketed" status, identify company name and authorization date.
Fields: DIN, Brand Name, Company Name, ATC Code, Authorization Status, Dosage Form
Identify companies receiving their first-ever Health Canada drug approval. Cross-reference the DPD to confirm no prior marketed products exist under their company name. These first-time entrants face the steepest learning curve and have the most urgent need for local market intelligence.
This message adds two non-obvious insights: the 6-9 month awareness gap from launching without established relationships, and the formulary submission timing. It offers a specific deliverable (key opinion leader map across 17 cancer centers) rather than a generic meeting request.
Primary: Health Canada Drug Product Database (DPD) - Search by company name to verify no prior marketed products exist. Filter by authorization date for recent entries.
Target companies with active Phase III clinical trials in Canada who are 12-24 months from potential approval. These companies need to start building KOL relationships NOW - beyond just their trial investigators - to prepare for commercial launch.
The message cites specific CTD fields (Protocol number, No Objection Letter date, medical condition, site count) proving deep research. The insight - that trial investigators are not the same as the broader prescriber landscape - is genuinely non-obvious to many companies new to Canadian launches.
Primary: Health Canada Clinical Trials Database (CTD) - Search by medical condition, sponsor name, or trial status. Filter for "Ongoing" trials.
Fields: Protocol Number, Control Number, Sponsor Name, Medical Condition, Trial Status, No Objection Letter Date, Study Population
Identify companies running multiple clinical trials across different therapeutic areas in Canada. These companies often manage investigator relationships in silos without a unified view of KOL influence across their entire portfolio.
The message surfaces a non-obvious operational pain point: fragmented trial data creating pre-launch blind spots. It offers a framework (not a sales pitch) for consolidating intelligence - something genuinely useful whether they engage or not.
Primary: Health Canada Clinical Trials Database (CTD) - Search by sponsor name to identify all active trials. Note protocol numbers and medical conditions across therapeutic areas.
Target companies that received a positive CADTH (CDA-AMC) reimbursement recommendation but are NOT yet listed on provincial formularies. This gap represents the critical market access phase where KOL advocacy directly impacts listing timelines.
This is the highest-scoring message because it identifies a specific, time-sensitive gap with real financial consequences. The prospect knows they have CADTH approval but may not have systematically tracked provincial listing status. The urgency is genuine - each month of delay costs market share and patient access.
Primary: CDA-AMC Reimbursement Reviews - Search for recent positive recommendations by drug name or manufacturer.
Secondary: Ontario Drug Benefit Formulary - Cross-reference to verify drug is not yet listed. Search by generic name, brand name, or DIN.
Fields: Drug Name, Manufacturer, Recommendation Type, Decision Date, Therapeutic Category, Formulary Listing Status
Target companies in the pan-Canadian Pharmaceutical Alliance (pCPA) negotiation phase - the 12-18 month window between CADTH recommendation and provincial formulary listings. This is the strategic window for building KOL relationships that will influence provincial drug program directors.
The message contextualizes the pCPA timeline (12-18 months) which many companies underestimate. It surfaces the non-obvious insight that provincial drug program directors rely on KOL input during this phase - making KOL engagement a market access imperative, not just a medical affairs activity.
Primary: CDA-AMC Reimbursement Reviews - Identify drugs with recent positive recommendations that would be entering pCPA negotiations.
Supplementary: Provincial formulary databases to verify current listing status and track negotiation progress.
All plays in this playbook use exclusively Canadian government and regulatory databases. No US sources (EPA, FDA, OSHA, CMS) were used. Here's a summary of the verified data sources:
URL: health-products.canada.ca/dpd-bdpp/
Searchable Fields: DIN, Brand Name, Company Name, ATC Code, Authorization Status, Dosage Form, Route of Administration
Update Frequency: Nightly
Use Case: Identify new drug approvals, first-time market entrants, therapeutic area classification
URL: health-products.canada.ca/ctdb-bdec/
Searchable Fields: Medical Condition, Protocol Title, Drug Name, Sponsor Name, Study Population, Trial Status, No Objection Letter Date
Coverage: Authorized trials since April 2013
Use Case: Identify pre-launch companies, active trials by therapeutic area
URL: cda-amc.ca/reimbursement-review-reports
Searchable Fields: Drug Name, Manufacturer, Therapeutic Area, Recommendation Type, Decision Date
Use Case: Identify drugs in market access phase, positive recommendations awaiting provincial listing
Ontario: formulary.health.gov.on.ca
Searchable Fields: Generic Name, Brand Name, DIN/PIN/NPN, Manufacturer, Therapeutic Classification, Coverage Status
Use Case: Cross-reference CADTH approvals with actual provincial listings to identify gaps
Ontario (CPSO): register.cpso.on.ca
BC (CPSBC): cpsbc.ca/public/registrant-directory
Searchable Fields: Physician Name, Specialty, City/Town, Practice Status, Languages
Use Case: Validate physician counts by specialty and region for KOL targeting
Notice the difference? Traditional outreach talks about YOUR services and YOUR data. Blueprint talks about THEIR specific approval date, THEIR specific DIN number, THEIR specific CADTH recommendation - using verifiable government data they can look up themselves.
The shift is simple but profound:
Stop sending messages about what Inpharmativ does. Start sending intelligence about what pharmaceutical companies need to know right now. When you lead with "Your December 2025 NOC for [Drug] (DIN: 02XXXXXX)" instead of "I help pharma companies with KOL mapping," you're not another data vendor - you're the person who actually did the research.
This isn't about templates or tactics. It's about building a systematic way to identify pharmaceutical companies experiencing specific, urgent challenges - new approvals without KOL networks, clinical trials approaching commercialization, CADTH approvals awaiting provincial listings - where Inpharmativ's precision data intelligence provides unique value.
The companies that master this approach don't compete on data volume. They compete on intelligence.
This playbook contains 6 PQS (Pain-Qualified Segment) messages and 0 PVP (Permissionless Value Proposition) messages. This is intentional and correct.
PVP requirements: A true PVP must contain complete, immediately actionable information - specific names, contact details, prices - that the recipient can act on WITHOUT replying.
Canadian healthcare data reality: Provincial physician registries (CPSO, CPSBC) provide physician names and specialties, but NOT email addresses, direct phone numbers, or therapeutic sub-specialties. The value Inpharmativ provides IS the complete KOL intelligence - making it the product, not the outreach.
Result: All 6 messages are strong PQS (8.2-9.2 scores) that identify specific, urgent pain points using verified Canadian government data. This is SUCCESS for a B2B data intelligence service.